Clinical trials
Advanced Malignant Tumors clinical trials
Below are recruiting advanced malignant tumors clinical trials, each written for real people, not researchers. We’re tracking 1,019 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07664150RecruitingPhase 1/Phase 2
Testing a new drug for HER2-positive cancers after other treatments stop working
This trial tests a new drug, CAN016, for people with advanced solid tumors that have HER2 expression or a HER2 gene change. You may qualify if your cancer has gotten worse after trying other HER2-targeted treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07656090Enrolling by invitationEarly Phase 1
Testing IDOV-Immune for advanced solid tumors
This trial tests an investigational drug called IDOV-Immune for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07623850RecruitingPhase 1
Early Study of JLM019 Injection for Advanced Cancers
This is an early-stage trial testing a new cancer treatment called JLM019 in patients with advanced solid tumors or lymphomas that haven't responded to other treatments. The study aims to find the right dose and see how well the drug works and how patients tolerate it.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07627334Recruiting
Personalized drug testing for newly diagnosed brain tumors
This trial tests whether customized drug screening on your tumor cells can help doctors choose the best treatment for you. Your tumor cells will be grown in the lab and tested against different drugs to find what works best, combined with short-course radiation therapy.
Vienna, State of ViennaAges Any age - NCT05667194RecruitingPhase 1
Early study of KH617 for advanced brain and solid tumors
This Phase 1 trial tests KH617, a new treatment, in adults with advanced cancers to see if it can be given safely and whether it shows signs of benefit. It is especially focused on tumors that have few or no standard treatment options, including certain brain tumor recurrences.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07600476RecruitingPhase 1
Safety Study of KUP-101A in Advanced Solid Tumors
This is an early-stage study testing a new drug called KUP-101A in patients with advanced solid cancers (like lung, colon, or breast cancer) that haven't responded to standard treatments. The drug works by activating the immune system to fight cancer.
Munich, BavariaAges 18 years+ - NCT06720324RecruitingPhase 1/Phase 2
CD7-targeted CAR-T therapy for relapsed blood cancers
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a specific marker called CD7 on blood cancer cells. It is for people whose blood cancer has not responded to other treatments or has come back after treatment.
Wuhan, HubeiAges 3–75 - NCT07560943RecruitingPhase 1
AI-Designed Cancer Vaccine for Advanced Solid Tumors
This trial tests a new mRNA vaccine designed by artificial intelligence to treat advanced cancers that have stopped responding to standard chemotherapy. The vaccine is personalized to each patient's tumor and aims to help the immune system fight remaining cancer cells.
Chengdu, SichuanAges 18–70 - NCT06281678RecruitingPhase 2
Study of IBI363 for advanced solid tumors
This trial tests a new drug called IBI363 for people with advanced solid tumors. It aims to see if the drug is safe and effective. You may be able to join if you are generally well and have not had other cancer treatments recently.
San Francisco, CaliforniaAges 18 years+ - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
Plantation, FloridaAges 18–99 - NCT07514065RecruitingPhase 1
TSL2109 Safety and Effectiveness Study in Advanced Cancers
This early-stage study tests a new drug called TSL2109 in patients with advanced solid cancers that haven't responded to standard treatment. Researchers want to find the right dose, understand how the body processes it, and see if it can slow or shrink tumors, with special focus on certain prostate and breast cancers.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07510321Recruiting
A study of FL-261 imaging for cancer diagnosis
This trial tests a new imaging agent called FL-261 to help doctors see and stage cancers more clearly. If you have a known or suspected cancer like lung, colon, or head and neck cancer, this study may improve how your cancer is evaluated.
Wuhan, HubeiAges 18 years+ - NCT06763159RecruitingPhase 1
Study of HS-20124 for advanced solid tumors
This study tests a new drug called HS-20124 for people with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and how well it works.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07456046RecruitingPhase 1
Study of D3S-003 for advanced solid tumors with KRAS G12D mutation
This trial tests a new medicine called D3S-003 in people whose cancer has a specific change (mutation) known as KRAS G12D. The medicine aims to target and attack cancer cells with this mutation. It may be an option if standard treatments have stopped working or are not available.
New Haven, ConnecticutAges 18 years+ - NCT06346041RecruitingEarly Phase 1
Testing a new IV drug IDOV-SAFE for advanced solid tumors
This trial tests a new intravenous drug called IDOV-SAFE in people with advanced solid tumors that have stopped responding to standard treatments or have no effective standard option. The goal is to see if it is safe and effective.
BeijingAges 18–75 - NCT07439120RecruitingEarly Phase 1
Testing a new radioactive drug for advanced solid tumors
This trial tests a new radioactive drug called 68Ga/177Lu-BRP-020063 in people with advanced solid tumors, especially bladder or breast cancer. The drug seeks out Nectin-4 on cancer cells, helping doctors see and potentially treat the tumors. The goal is to check that the drug is safe and tolerable.
ShanghaiAges 18 years+ - NCT07426094RecruitingPhase 2/Phase 3
Boosting radiation for prostate cancer in lymph nodes
This trial tests whether giving higher radiation doses to the prostate and pelvic lymph nodes is more effective than treating only the prostate. You may benefit if your prostate cancer has spread to nearby lymph nodes but not to bones or other organs, and you are getting hormone therapy.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT07381829RecruitingPhase 1
HC010 plus chemotherapy for advanced lung cancer
This trial tests an experimental drug called HC010 combined with chemotherapy for people with advanced lung cancer, including certain types of non-small cell or small cell lung cancer. It aims to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT07387081RecruitingPhase 2
Study of LM-24C5 for advanced solid tumors
This trial tests a new drug, LM-24C5, for people with advanced solid tumors that have come back or not responded to treatment. It may be an option if your tumor has a specific marker called CEACAM5.
Fuzhou, FujianAges 18–80 - NCT07292038RecruitingPhase 1
Testing NM6603 in advanced solid tumors
This study tests an experimental oral drug called NM6603 in people with advanced solid tumors, especially colorectal cancer or triple-negative breast cancer. It aims to find a safe dose and see how the drug works in the body.
Xiamen, FujianAges 18–75 - NCT07287917RecruitingPhase 1/Phase 2
Testing a new drug combo for advanced breast cancer or melanoma
This trial tests a new combination of drugs (AMXT 1501, DFMO, and standard therapies) for people with advanced solid tumors, specifically breast cancer (ER+ HER2-) or melanoma that has progressed after other treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Tucson, ArizonaAges 18 years+ - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Goodyear, ArizonaAges 18 years+ - NCT07277270RecruitingPhase 1
Study of a new drug with standard treatments for advanced solid tumors
This trial tests a new investigational drug called GSK5764227 when given along with standard cancer treatments or other drugs for people with advanced colorectal or prostate cancer that has spread and cannot be removed by surgery.
Reunion, FloridaAges 18 years+ - NCT07276373RecruitingPhase 1/Phase 2
Nenocorilant with nivolumab for advanced solid tumors
This trial tests a new drug called nenocorilant combined with nivolumab (an immunotherapy) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if this combination is safe and effective.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Advanced Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced malignant tumors?
- Yes. Clin2 currently lists 1,019 recruiting advanced malignant tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced malignant tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced malignant tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.